|
English
|
正體中文
|
简体中文
|
0
|
|
???header.visitor??? :
53266635
???header.onlineuser??? :
696
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"kaseb a"???jsp.browse.items-by-author.description???
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國家衛生研究院 |
2025-07 |
Neoadjuvant immunotherapy is associated with a recurrence free survival benefit versus active surveillance in patients with resected hepatocellular cancer
|
Brunetti, L;D'Alessio, A;Fulgenzi, CAM;Yarchoan, M;Marron, T;Blanter, J;Torkpour, A;Lombardi, P;Baretti, M;Crowley, F;Hsu, C;Cortellini, A;Su, YY;Lee, PC;Eid, JR;Kaseb, A;Pinato, DJ |
| 臺大學術典藏 |
2022-02-21T02:04:34Z |
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
|
Galle P.R.; Finn R.S.; Qin S.; Ikeda M.; Zhu A.X.; Kim T.-Y.; Kudo M.; Breder V.; Merle P.; Kaseb A.; Li D.; Mulla S.; Verret W.; Xu D.-Z.; Hernandez S.; Ding B.; Liu J.; Huang C.; Lim H.Y.; ANN-LII CHENG; Ducreux M. |
| 臺大學術典藏 |
2021-08-31T06:29:17Z |
IMbrave 050: A Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation
|
Hack S.P.; Spahn J.; Chen M.; ANN-LII CHENG; Kaseb A.; Kudo M.; Lee H.C.; Yopp A.; Chow P.; Qin S. |
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
